Thiazolidinediones in dermatologyBOYD, Alan S.International journal of dermatology. 2007, Vol 46, Num 6, pp 557-563, issn 0011-9059, 7 p.Article

ThiazolidinedionesYKI-JÄRVINEN, Hannele.The New England journal of medicine. 2004, Vol 351, Num 11, pp 1106-1118, issn 0028-4793, 13 p.Article

Sequence variation in PPARG may underlie differential response to troglitazoneWOLFORD, Johanna K; YEATTS, Kimberly A; DHANJAL, Sharanjeet K et al.Diabetes (New York, NY). 2005, Vol 54, Num 11, pp 3319-3325, issn 0012-1797, 7 p.Article

Troglitazone : the lesson that nobody learned?GALE, Edwin A. M.Diabetologia (Berlin). 2006, Vol 49, Num 1, pp 1-6, issn 0012-186X, 6 p.Article

Visfatin is an adipokine, but it is not regulated by thiazolidinedionesHAMMARSTEDT, Ann; PIHLAJAMÄKI, Jussi; SOPASAKIS, Victoria Rotter et al.The Journal of clinical endocrinology and metabolism. 2006, Vol 91, Num 3, pp 1181-1184, issn 0021-972X, 4 p.Article

Thiazolidinediones and fluid retentionKIRYLUK, K; ISOM, R.Kidney international. 2007, Vol 72, Num 6, pp 762-768, issn 0085-2538, 7 p.Article

Pleiotropic actions of PPARγ activators thiazolidinediones in cardiovascular diseasesTAKANO, Hiroyuki; HASEGAWA, Hiroshi; ZOU, Yunzeng et al.Current pharmaceutical design. 2004, Vol 10, Num 22, pp 2779-2786, issn 1381-6128, 8 p.Article

Ineffectiveness of rosiglitazone therapy in nelson's syndromeMUNIR, A; SONG, F; INCE, P et al.The Journal of clinical endocrinology and metabolism. 2007, Vol 92, Num 5, pp 1758-1763, issn 0021-972X, 6 p.Article

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged boneLAZARENKO, Oxana P; RZONCA, Sylwia O; HOGUE, William R et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 6, pp 2669-2680, issn 0013-7227, 12 p.Article

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedioneEMOTO, M; FUKUDA, N; NAKAMORI, Y et al.Diabetologia (Berlin). 2006, Vol 49, Num 9, pp 2217-2218, issn 0012-186X, 2 p.Article

Avandamet° : Remboursement des dosages forts = Avandamet° : repayment of high doseLa Revue Prescrire. 2005, Vol 25, Num 263, issn 0247-7750, p. 502Article

Severe hypo-α-lipoproteinemia during treatment with rosiglitazoneSARKER, Anita; SEMPLE, Robert K; DINNEEN, Sean F et al.Diabetes care. 2004, Vol 27, Num 11, pp 2577-2580, issn 0149-5992, 4 p.Article

Ontology-based knowledge management of troglitazone-induced hepatotoxicityHUG, Hubert; DANNECKER, Robert; SCHINDLER, Richard et al.Drug discovery today. 2004, Vol 9, Num 22, pp 948-954, issn 1359-6446, 7 p.Article

Effects of troglitazone in young first-degree Relatives of patients with type 2 diabetesLEVIN, Klaus; HOTHER-NIELSEN, Ole; HENRIKSEN, Jan Erik et al.Diabetes care. 2004, Vol 27, Num 1, pp 148-154, issn 0149-5992, 7 p.Article

Progress with thiazolidinediones in the management of type 2 diabetes mellitusMERIDEN, Terry.Clinical therapeutics. 2004, Vol 26, Num 2, pp 177-190, issn 0149-2918, 14 p.Article

Thiazolidinediones: metabolic actions in vitroFÜRNSINN, C; WALDHÄUSL, W.Diabetologia (Berlin). 2002, Vol 45, Num 9, pp 1211-1223, issn 0012-186X, 13 p.Article

Rosiglitazone evaluated for cardiovascular outcomes - : An interim analysisHOME, Philip D; POCOCK, Stuart J; BECK-NIELSEN, Henning et al.The New England journal of medicine. 2007, Vol 357, Num 1, pp 28-38, issn 0028-4793, 11 p.Article

Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissueGOLDFINE, Allison B; CRUNKHORN, Sarah; PATTI, Mary Elizabeth et al.Diabetes (New York, NY). 2006, Vol 55, Num 3, pp 640-650, issn 0012-1797, 11 p.Article

Adiponectin-dependent and -independent pathways in insulin-sensitizing and antidiabetic actions of thiazolidinedionesKUBOTA, Naoto; YAMAUCHI, Toshimasa; TOBE, Kazuyuki et al.Diabetes (New York, NY). 2006, Vol 55, issn 0012-1797, S32-S38, SUP2Conference Paper

Thiazolidinedione derivatives in type 2 diabetes mellitusTACK, C. J. J; SMITS, P.Netherlands journal of medicine. 2006, Vol 64, Num 6, pp 166-174, issn 0300-2977, 9 p.Article

Clinical implications of the DREAM study. CommentaryDAVIDSON, Mayer B.Diabetes care. 2007, Vol 30, Num 2, pp 418-420, issn 0149-5992, 3 p.Article

Treatment of necrobiosis lipoidica with pioglitazoneBOYD, Alan S.Journal of the American Academy of Dermatology. 2007, Vol 57, Num 5, issn 0190-9622, S120-S121, SUPArticle

Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro : Potential for interactions with CYP2C8 inhibitorsJAAKKOLA, Tiina; LAITILA, Jouko; NEUVONEN, Pertti J et al.Basic & clinical pharmacology & toxicology (Print). 2006, Vol 99, Num 1, pp 44-51, issn 1742-7835, 8 p.Article

Thiazolidinedione use and bone loss in older diabetic adultsSCHWARTZ, Ann V; SELLMEYER, Deborah E; SEOK WON PARK et al.The Journal of clinical endocrinology and metabolism. 2006, Vol 91, Num 9, pp 3349-3354, issn 0021-972X, 6 p.Article

The pharmacokinetics of pioglitazone in Thai healthy subjectsWITTAYALERTPANYA, Supeecha; CHOMPOOTAWEEP, Sumana; THAWORN, Nongnuch et al.Chot Mai Het Thang Phaet. 2006, Vol 89, Num 12, pp 2116-2122, issn 0125-2208, 7 p.Article